Characterization of CD24 expression in intraductal papillary mucinous neoplasms and ductal carcinoma of the pancreas
Characterization of CD24 expression in intraductal papillary mucinous neoplasms and ductal carcinoma of the pancreas
复制标题
DOI：
10.1016/j.humpath.2010.04.004
复制
发表时间：
2010-10-01
期刊：
影响因子：
3.3
通讯作者：
Tanaka, Masao
中科院分区：
文献类型：
--
作者：
Ikenaga, Naoki;Ohuchida, Kenoki;Tanaka, Masao
CD 24是参与细胞粘附和肿瘤转移的分子。本研究的目的是（1）评估CD 24表达与胰腺导管内乳头状粘液性肿瘤进展之间的关系，（2）研究胰腺癌中CD 24表达与接受根治性胰腺切除术患者预后之间的关系。对95例胰腺导管内乳头状黏液性肿瘤和83例胰腺癌进行了CD 24的免疫组化分析。我们研究了CD 24表达与胰腺导管内乳头状黏液性肿瘤的组织学分级、胰腺癌的临床病理参数以及接受胰腺切除术的胰腺癌患者的生存时间之间的关系。导管内乳头状黏液腺瘤、导管内交界性乳头状黏液肿瘤、非浸润性导管内乳头状黏液癌和浸润性导管内乳头状黏液癌中CD 24阳性表达率分别为5/24（20%）、12/25（48%）、10/23（43%）和15/23（65%）。与导管内乳头状黏液性腺瘤相比，导管内乳头状黏液性肿瘤和导管内乳头状黏液性癌的CD 24阳性率显著更高（分别为P = 0.046和P = 0.007）。浸润性导管内乳头状黏液癌的染色评分（由染色细胞百分比和染色强度确定）显著高于非浸润性导管内乳头状黏液癌（P = 0.043）。在胰腺癌中，与CD 24阴性组相比，CD 24阳性组的肿瘤分期较高（P = .007）、淋巴结转移（P = .021）和肿瘤级别较高（P < .001）。在单因素分析中，CD 24表达与较短的生存期相关（P = 0.028），然而，基于多因素分析，CD 24表达与生存期无关。总之，CD 24参与了胰腺导管内乳头状粘液性肿瘤的进展和胰腺癌的恶性行为。(C)2010年爱思唯尔公司All rights reserved.
CD24 is a molecule involved in cell adhesion and tumor metastasis. The aims of this study were (1) to evaluate the association between CD24 expression and the progression of intraductal papillary mucinous neoplasms of the pancreas and (2) to investigate the association between CD24 expression in pancreatic cancer and the prognosis of patients who underwent curative pancreatectomy. Immunohistochemical analysis of CD24 was performed for 95 intraductal papillary mucinous neoplasms of the pancreas and 83 pancreatic cancers. We investigated the association between CD24 expression and the histologic grade of intraductal papillary mucinous neoplasms of the pancreas, the clinicopathologic parameters of pancreatic cancers, and the survival time of pancreatic cancer patients who underwent pancreatectomy. The positive rates of CD24 expression in intraductal papillary mucinous adenoma, borderline intraductal papillary mucinous neoplasm, noninvasive intraductal papillary mucinous carcinoma, and invasive intraductal papillary mucinous carcinoma were 5 (20%) of 24, 12 (48%) of 25, 10 (43%) of 23, and 15 (65%) of 23, respectively. The CD24-positive rates were significantly higher in borderline intraductal papillary mucinous neoplasm and intraductal papillary mucinous carcinoma compared with intraductal papillary mucinous adenoma (P = .046 and P = .007, respectively). The staining scores, which were determined from the percentage of stained cells and the staining intensity, were significantly higher in invasive intraductal papillary mucinous carcinoma than in noninvasive intraductal papillary mucinous carcinoma (P = .043). In the pancreatic cancers, higher tumor stage (P = .007), nodal metastasis (P = .021), and higher-grade tumors (P < .001) were more frequent in the CD24-positive group compared with the CD24-negative group. CD24 expression was associated with shorter survival in univariate analysis (P = .028) However, based on the multivariate analysis, the CD24 expression was not associated with survival. In conclusion, CD24 is involved in the progression of intraductal papillary mucinous neoplasms of the pancreas and in the malignant behavior of pancreatic cancers. (C) 2010 Elsevier Inc. All rights reserved.